[Survivin supressant: a promising target for cancer therapy and pharmacological profiles of YM155].
aya.kita@jp.astellas.com
Aya
A
Kita
Takahito
T
Nakahara
Masahiro
M
Takeuchi
Isao
I
Kinoyama
Kentaro
K
Yamanaka
Tsuyoshi
T
Minematsu
Keisuke
K
Mitsuoka
Hiroshi
H
Fushiki
Sousuke
S
Miyoshi
Masao
M
Sasamata
Keiji
K
Miyata
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D051034:Inhibitor of Apoptosis Proteins; D051379:Mice; D008869:Microtubule-Associated Proteins / Q000037:antagonists & inhibitors*; D009285:Naphthoquinones / Q000627:therapeutic use*; D000077022:Survivin; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D007093:Imidazoles; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009285:Naphthoquinones; D000077022:Survivin; C523798:sepantronium